The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDuke Capital Regulatory News (DUKE)

Share Price Information for Duke Capital (DUKE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 31.25
Bid: 31.00
Ask: 31.50
Change: 0.25 (0.81%)
Spread: 0.50 (1.613%)
Open: 31.25
High: 31.30
Low: 31.25
Prev. Close: 31.00
DUKE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update and Notice of FY 2020 Results

6 Aug 2020 07:00

RNS Number : 2816V
Duke Royalty Limited
06 August 2020
 

6 August 2020

Duke Royalty Limited

("Duke Royalty", "Duke" or the "Company")

 

Trading Update & Notice of FY 2020 Results

 

Duke Royalty, a provider of alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad, is pleased to provide the following trading update for Q1 FY2021.

 

Additionally, Duke Royalty announces that its Full Year results for the financial year ended 31 March 2020 (FY2020) are expected to be published on 17 September 2020.

 

Current Trading

Duke Royalty is pleased to report that most of its Royalty Partners have experienced a significant upturn in trading during May and June, further to the reduction in revenue experienced by most of its Royalty Partners at the start of the pandemic as described in our previous trading update. The general upturn in trading has continued into Q2 FY2021.

 

The Company is therefore pleased to report that Q1 FY2021 cash revenue, being cash distributions from its Royalty Partners and cash gains from sales of equity assets, totalled over £2.0 million. Duke's cash revenue therefore was only down 20% from the comparable quarter a year ago, while its operating cash costs decreased 15% from the same period 12 months ago, on the back of the decisive action taken by Duke in regards to its cost base at the start of the pandemic.

 

On this basis, it is important to note that the Company's Q1 cash revenue would surpass the full year operating cash costs. In addition, Duke estimates that the cash revenue it will receive from its Royalty Partners in Q2 FY2021 will exceed Q1 FY2021.

 

Since April, the Company has focused its efforts on ensuring that its Royalty Partners most impacted by the Covid-19 pandemic have been given the financial flexibility to manage the challenges they are experiencing in relation to cash flow, while also backing those Royalty Partners who are benefitting in the current climate. In certain circumstances, forbearance agreements have been structured to cover the six-month period ending September 2020. Rather than surrendering its revenue, these agreements mean Duke's forgone cash distributions for the first six months of the pandemic have been either accrued, capitalised or equitized.

 

Although it is clear that the macro environment is still highly volatile and uncertain, and that this is expected to continue for the foreseeable future, based on current trading, Duke does not expect that these agreements will need to be extended.

 

With this in mind, as the current forbearance agreements expire and are replaced with normalised monthly cash payments from most of its Royalty Partners commencing October 2020, the Company is cautiously optimistic that it will be able to announce a positive trend of increasing quarterly cash revenues over the coming quarters and that quarterly cash revenue growth will accelerate further into Q3 FY2021.

 

Neil Johnson, CEO of Duke Royalty, said:

"I am pleased to report that the feedback from our Royalty Partners is one of a relatively improving operating environment and that we are beginning to see some positive momentum re-emerging from the portfolio as a whole, notwithstanding the fact that we continue to face an unprecedented operating environment.

 

"While the long-term outlook for each Royalty Partner varies, Duke has taken a series of proactive measures to help its few hardest hit, consumer-facing Royalty Partners. All of the businesses within our portfolio have withstood prior market turbulence and have a long term track record of profitability and growth, so we support them as they navigate their way through this difficult trading period.

 

"I firmly believe that the recent challenging operating environment has strengthened the relationship that Duke has with its current Royalty Partners and has provided confirmation that Duke is a long term and supportive capital provider."

***ENDS***

 

For further information, please contact www.dukeroyalty.com, or contact:

 

Duke Royalty Limited

Neil Johnson / Charlie Cannon-Brookes / Hugo Evans

 

+44 (0) 1481 741 240

Cenkos Securities plc 

(Nominated Adviser and Broker)

 

Julian Morse / Michael Johnson / Stephen Keys / Callum Davidson

+44 (0) 207 397 8900

Newgate Communications

(PR)

 

Elisabeth Cowell / Ian Silvera / Megan Kovach

+44 (0) 20 3757 6880

Dukeroyalty@newgatecomms.com

 

About Duke Royalty

 

Duke Royalty Limited provides alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad. Duke Royalty's experienced team provide financing solutions to private companies that are in need of capital but whose owners wish to maintain equity control of their business. Duke Royalty's royalty investments are intended to provide robust, stable, long term returns to its shareholders. Duke Royalty is listed on the AIM market under the ticker DUKE and is headquartered in Guernsey.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTFLFLRTLIEIII
Date   Source Headline
3rd Apr 20247:00 amRNSFollow-On Investment into Existing Capital Partner
2nd Apr 20247:00 amRNSNew Capital Partner - Integrum Care
28th Mar 20247:00 amRNSTrading and Operational Update
21st Mar 20247:00 amRNSInterim Dividend and Dividend Declaration
7th Mar 20247:00 amRNSSuccessful Exit of Investment in Fabrikat
6th Mar 20247:00 amRNSSuccessful Exit of Investment
4th Mar 20247:00 amRNSIncreased Equity Stake in United Glass Group
21st Feb 202411:57 amRNSName Change Effective
20th Feb 202412:08 pmRNSResult of General Meeting & Change of Name
5th Feb 20247:00 amRNSProposed Change of Name, Website and Messaging
29th Dec 20237:00 amRNSTrading Update and Follow-on Investment
19th Dec 20237:00 amRNSInterim Dividend and Dividend Declaration
29th Nov 20237:00 amRNSUpdate re. Change of Name of Nominated Adviser
22nd Nov 20237:00 amRNSFinancial Year 2024 Interim Results
21st Sep 20237:00 amRNSInterim Dividend and Dividend Declaration
13th Sep 20237:00 amRNSTrading Update
2nd Aug 20234:51 pmRNSResult of Annual General Meeting
31st Jul 20237:00 amRNSNew Royalty Agreement
28th Jul 20237:00 amRNSDirector/PDMR Dealings
20th Jul 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
4th Jul 20237:00 amRNSFinal Results for the year ended 31 March 2023
3rd Jul 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
26th Jun 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
15th Jun 20237:00 amRNSInterim Dividend and Dividend Declaration
9th Jun 20237:00 amRNSNotice of Results
1st Jun 20237:00 amRNSTrading Update
25th May 20237:00 amRNSDirectors' Dealings
24th May 20237:00 amRNSSuccessful Exit of Investment in Royalty Partner
22nd Mar 20237:00 amRNSInterim Dividend and Dividend Declaration
7th Mar 20237:00 amRNSNew Royalty Agreement
3rd Mar 20237:00 amRNSTrading Update
21st Feb 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
16th Jan 20237:00 amRNSClosing of New Credit Facility
15th Dec 20223:35 pmRNSInterim Dividend and Dividend Declaration
13th Dec 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
12th Dec 20227:00 amRNSRefinance and Upsize of Credit Facility
1st Dec 20227:01 amRNSTrading Update
1st Dec 20227:00 amRNS2023 Interim Results
29th Nov 202212:38 pmRNSResult of Annual General Meeting
25th Nov 20227:00 amRNSNew Royalty Agreement
14th Nov 20227:00 amRNSNotice of AGM and Notice of Interim Results
14th Oct 20227:00 amRNSPSAs, Issue of Equity & Director/PDMR Dealings
22nd Sep 20227:00 amRNSInterim Dividend and Dividend Declaration
13th Sep 20229:09 amRNSPublication of Annual Report & Accounts
9th Sep 20227:00 amRNSPostponement of Presentation
8th Sep 20227:00 amRNSFinal Results for the year ended 31 March 2022
31st Aug 20225:04 pmRNSHolding(s) in Company
30th Aug 20223:07 pmRNSHolding(s) in Company
5th Aug 20227:00 amRNSNotice of Results and Presentations
4th Aug 20227:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.